Financial Performance - The Group's revenue for the Relevant Period was $5.9 million, representing a decrease of $2.7 million or 31.4% compared to $8.7 million in the Previous Period[7]. - The Group's profit for the Relevant Period was $166,000, down from a profit of $363,000 in the Previous Period[7]. - Gross profit for 2021Q2 was $1.559 million, compared to $1.992 million in 2020Q2[11]. - Revenue from external customers for Q2 2021 was $5,934,000, a decrease of 31.5% compared to $8,650,000 in Q2 2020[67][81]. - Reportable segment profit for Q2 2021 was $1,559,000, down 21.7% from $1,992,000 in Q2 2020[91][87]. - Consolidated profit before taxation for Q2 2021 was $226,000, a decline of 50.1% from $453,000 in Q2 2020[91]. - The profit and total comprehensive income for the period was $363,000[20]. - The Group's basic and diluted earnings per share for 2021Q2 were 0.02 cents, down from 0.05 cents in 2020Q2[11]. - Basic earnings per share for Q2 2021 was 0.02 cents, down from 0.05 cents in Q2 2020[123]. - The Group did not declare any dividends for Q2 2021, consistent with Q2 2020[126]. Assets and Liabilities - Total assets as of March 31, 2021, amounted to $26.378 million, slightly up from $26.232 million as of September 30, 2020[16]. - Total liabilities as of March 31, 2021, were $10.524 million, compared to $10.544 million as of September 30, 2020[16]. - As of March 31, 2021, total equity amounted to $15,854,000, an increase from $15,688,000 on October 1, 2020[23]. - Current assets included inventories of $6.982 million and cash and cash equivalents of $14.413 million as of March 31, 2021[16]. - As of March 31, 2021, trade receivables decreased to $1,688,000 from $3,051,000 as of September 30, 2020, representing a reduction of approximately 44.6%[138]. - Trade payables decreased to $787,000 as of March 31, 2021, down from $1,647,000 as of September 30, 2020, indicating a decline of approximately 52.2%[192]. - Borrowings as of March 31, 2021, include a Singapore government loan of $7,000,000, unchanged from September 30, 2020, which is interest-free and unsecured[185]. Cash Flow - Net cash used in operating activities for Q2 2021 was $(180,000), an improvement from $(771,000) in Q2 2020[26]. - Net cash used in investing activities for Q2 2021 was $(685,000), compared to $(1,970,000) in Q2 2020, indicating reduced investment outflows[26]. - Cash and cash equivalents at the end of Q2 2021 were $3,012,000, down from $4,224,000 at the end of Q2 2020[26]. - The company reported a net decrease in cash and cash equivalents of $(936,000) for Q2 2021, compared to $(2,804,000) in Q2 2020[26]. Expenses - Selling and distribution expenses for the Relevant Period were $709,000, a decrease from $863,000 in the Previous Period[11]. - The Group incurred progressive costs of $293,000 for factory extension in Q2 2021, significantly lower than $1.6 million in Q2 2020[127]. - Total unallocated expenses for Q2 2021 were $1,479,000, reduced from $1,708,000 in Q2 2020[91]. - Interest expenses for Q2 2021 were $8,000, slightly up from $5,000 in Q2 2020[91]. - The company invested $293,000 in expanding its existing factory and incurred costs of $475,000 for truck purchases in the second quarter of 2021, compared to $1,600,000 in the second quarter of 2020[130]. Company Overview - The company primarily supplies tissue products to corporate customers in Singapore, focusing on tissue and hygiene-related products[36]. - The immediate and ultimate holding company is YJH Group, incorporated in the British Virgin Islands[28]. - The company has not early adopted any new IFRSs that are not yet effective, anticipating no material impact on financial statements[32]. - The unaudited condensed consolidated financial statements are prepared in accordance with International Accounting Standard 34, with all financial information presented in SGD[31]. - The Group's non-current assets are entirely located in Singapore, with operations also based there[92]. Future Outlook - The company is optimistic about recovery as Singapore entered phase three of reopening on December 28, 2020[200]. - The company will continue to evaluate development opportunities to strengthen its competitive advantage and market-leading position[200]. - The company aims to achieve sustainable growth and is committed to delivering greater returns to shareholders[200]. - The company is monitoring new tissue product developments and sourcing competitively priced tissue products[200]. - The company has built strong ties with customers and suppliers over the past 43 years, ensuring product delivery satisfaction[200]. Management and Compensation - Key management personnel compensation for Q2 2021 was $410,000, a slight decrease from $422,000 in Q2 2020[196]. Retained Earnings and Impairment - Retained earnings increased to $2,420,000 as of March 31, 2021, up from $2,254,000 as of September 30, 2020, reflecting a growth of approximately 7.4%[180]. - The allowance for impairment on trade receivables was recorded at $1,000 as of March 31, 2021, indicating a minimal impact on the overall receivables[138]. - The company expects trade receivables to be recovered within one year, reflecting a stable cash flow outlook[134]. - The revaluation reserve remains at $5,295,000 as of March 31, 2021, unchanged from September 30, 2020, indicating stability in asset valuation[177].
日光控股(08451) - 2021 - 中期财报